FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 60 filers reported holding FATE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $7,372,346 | -47.3% | 2,247,383 | +17.9% | 0.00% | 0.0% |
Q1 2024 | $13,991,921 | +100.7% | 1,905,983 | +2.3% | 0.00% | 0.0% |
Q4 2023 | $6,970,176 | +85.2% | 1,863,485 | +5.0% | 0.00% | – |
Q3 2023 | $3,764,193 | -54.7% | 1,775,344 | +1.7% | 0.00% | -100.0% |
Q2 2023 | $8,306,737 | -9.6% | 1,745,112 | +8.2% | 0.00% | 0.0% |
Q1 2023 | $9,191,763 | +58138.4% | 1,612,589 | +3.1% | 0.00% | -50.0% |
Q4 2022 | $15,783 | -100.0% | 1,564,291 | +4.3% | 0.00% | -60.0% |
Q3 2022 | $33,607,000 | -7.5% | 1,499,680 | +2.3% | 0.01% | 0.0% |
Q2 2022 | $36,319,000 | -36.5% | 1,465,678 | -0.6% | 0.01% | -28.6% |
Q1 2022 | $57,155,000 | -31.5% | 1,474,227 | +3.4% | 0.01% | -30.0% |
Q4 2021 | $83,433,000 | +0.3% | 1,425,968 | +1.6% | 0.01% | -9.1% |
Q3 2021 | $83,220,000 | -32.4% | 1,404,096 | -1.0% | 0.01% | -35.3% |
Q2 2021 | $123,103,000 | +10.7% | 1,418,406 | +5.1% | 0.02% | 0.0% |
Q1 2021 | $111,250,000 | +5.5% | 1,349,312 | +16.4% | 0.02% | -5.6% |
Q4 2020 | $105,434,000 | +139.0% | 1,159,514 | +5.1% | 0.02% | +100.0% |
Q3 2020 | $44,106,000 | +24.6% | 1,103,490 | +7.0% | 0.01% | +12.5% |
Q2 2020 | $35,384,000 | +67.9% | 1,031,326 | +8.7% | 0.01% | +60.0% |
Q1 2020 | $21,072,000 | -38.6% | 948,788 | -45.9% | 0.01% | +25.0% |
Q4 2019 | $34,318,000 | +172.0% | 1,753,670 | +115.8% | 0.00% | +33.3% |
Q3 2019 | $12,618,000 | -22.6% | 812,533 | +1.2% | 0.00% | -25.0% |
Q2 2019 | $16,299,000 | +17.3% | 802,953 | +1.5% | 0.00% | 0.0% |
Q1 2019 | $13,895,000 | -22.9% | 790,871 | -43.7% | 0.00% | +33.3% |
Q4 2018 | $18,016,000 | +114.7% | 1,404,358 | +172.6% | 0.00% | +50.0% |
Q3 2018 | $8,393,000 | +63.4% | 515,252 | +13.8% | 0.00% | 0.0% |
Q2 2018 | $5,136,000 | +30.1% | 452,926 | +11.9% | 0.00% | +100.0% |
Q1 2018 | $3,949,000 | +86.0% | 404,634 | +16.4% | 0.00% | 0.0% |
Q4 2017 | $2,123,000 | +77.4% | 347,573 | +14.9% | 0.00% | – |
Q3 2017 | $1,197,000 | +108.9% | 302,431 | +70.8% | 0.00% | – |
Q2 2017 | $573,000 | +5.5% | 177,082 | +48.2% | 0.00% | – |
Q1 2017 | $543,000 | +87.9% | 119,514 | +3.6% | 0.00% | – |
Q4 2016 | $289,000 | -14.2% | 115,416 | +6.8% | 0.00% | – |
Q3 2016 | $337,000 | +84.2% | 108,093 | +0.1% | 0.00% | – |
Q2 2016 | $183,000 | -5.7% | 108,029 | 0.0% | 0.00% | – |
Q1 2016 | $194,000 | -46.7% | 108,029 | -0.1% | 0.00% | – |
Q4 2015 | $364,000 | -36.7% | 108,093 | +0.1% | 0.00% | – |
Q3 2015 | $575,000 | +14.1% | 107,965 | +38.5% | 0.00% | – |
Q2 2015 | $504,000 | +227.3% | 77,947 | +146.9% | 0.00% | – |
Q1 2015 | $154,000 | -1.9% | 31,576 | +0.6% | 0.00% | – |
Q4 2014 | $157,000 | -1.9% | 31,384 | +0.6% | 0.00% | – |
Q3 2014 | $160,000 | +7.4% | 31,192 | +31.8% | 0.00% | – |
Q2 2014 | $149,000 | -35.5% | 23,664 | -0.3% | 0.00% | – |
Q1 2014 | $231,000 | – | 23,728 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |